(Q44597307)

English

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

scientific article published on 15 February 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta (English)

1 reference

Europe PubMed Central

4 December 2017

phase II clinical trial

0 references

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

author name string

Daniel Wynn

1

1 reference

Europe PubMed Central

4 December 2017

Michael Kaufman

2

1 reference

Europe PubMed Central

4 December 2017

Xavier Montalban

3

1 reference

Europe PubMed Central

4 December 2017

Timothy Vollmer

4

1 reference

Europe PubMed Central

4 December 2017

Jack Simon

5

1 reference

Europe PubMed Central

4 December 2017

Jacob Elkins

6

1 reference

Europe PubMed Central

4 December 2017

Gilmore O'Neill

7

1 reference

Europe PubMed Central

4 December 2017

Lauri Neyer

8

1 reference

Europe PubMed Central

4 December 2017

James Sheridan

9

1 reference

Europe PubMed Central

4 December 2017

Chungchi Wang

10

1 reference

Europe PubMed Central

4 December 2017

Alice Fong

11

1 reference

Europe PubMed Central

4 December 2017

John W Rose

12

1 reference

Europe PubMed Central

4 December 2017

CHOICE investigators

13

1 reference

Europe PubMed Central

4 December 2017

publication date

15 February 2010

1 reference

Europe PubMed Central

4 December 2017

Lancet Neurology

1 reference

Europe PubMed Central

4 December 2017

9

1 reference

Europe PubMed Central

4 December 2017

381-390

1 reference

Europe PubMed Central

4 December 2017

4

1 reference

Europe PubMed Central

4 December 2017

Advances in interleukin 2 receptor targeted treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk alleles for multiple sclerosis identified by a genomewide study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The complex genetics of multiple sclerosis: pitfalls and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Refining genetic associations in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970033-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(10)70033-8

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44597307&oldid=2029077084"